Novotech Partners with Kyungpook National University Hospital to Strengthen Clinical Trial Capabilities in South Korea
18.3.2025 13:05:00 CET | Business Wire | Press release
Novotech, a global leading full-service clinical Contract Research Organization (CRO), and Acrostar, a provider of Site Management Organization (SMO) services have entered into a strategic partnership by signing a Memorandum of Understanding (MOU) with Kyungpook National University Hospital (KNUH). The partnership will support clinical trials across KNUH’s prestigious institutions including the Advanced Clinical Trials Center, the KNUH main campus, and the Chilgok KNUH in South Korea.
This collaboration is a key milestone for the advanced clinical trials in South Korea, strategically aligning with the amendments to the Advanced Regenerative Bio Act. This agreement builds upon the recent inauguration of KNUH’s Advanced Clinical Trials Center opened in November last year, marking its first official partnership post-amendment of the Bio Act.
The amendments to the Advanced Regenerative Bio Act expanded the scope of advanced regenerative medicine, allowing the use of investigational therapies in clinical trials and expanding the number of authorized regenerative medicine institutions. Previously limited to severe, rare, and incurable diseases, regenerative medicine applications will now extend to a broader range of conditions, including general diseases.
Patients outside of clinical trials will also gain access to regenerative medicine services, while the range of applicable technologies—including cell and gene therapies (CGT) and tissue engineering—has significantly expanded.
Under the previous framework, CGTs required formal drug approval for clinical application. With these regulatory changes, CGTs in clinical trials can now be utilized upon review committee approval, streamlining access to innovative therapies.
The partnership creates a comprehensive framework across KNUH’s network with early-stage clinical trials primarily conducted at the Advanced Clinical Trials Center, while late-stage trials will be managed with the KNUH’s hospital system itself.
Speaking at the ceremony, Prof. Hyungran Yoon, Director of the Advanced Clinical Trials Center, spoke about the benefits of the collaboration, “The Advanced Clinical Trials Center will oversee trials for all diseases treated at KNUH, strengthening our role as a leader in clinical research and regenerative medicine. The partnership agreement with Novotech will expand their capacity to offer innovative treatment opportunities both domestically and internationally.”
Dr. Yooni Kim, Managing Director, Asia-Pacific at Novotech, highlighted the strategic advantages. “This partnership combines Novotech’s global expertise with KNUH’s specialized capabilities to offer cutting-edge treatment solution and streamlined trial operations. By leveraging this synergy, we aim to boost South Korea’s position on the global stage in regenerative medicine and enhance clinical trial excellence worldwide.”
This partnership also marks a significant milestone for Acrostar, Novotech’s SMO services provider. Daniel Kim, Director of Acrostar Asia-Pacific, shared his excitement about the partnership, “This is Acrostar’s first partnership in South Korea. Through this collaboration, we will actively support the site and ensure the smooth progress of clinical trials from a site management perspective.”
This strategic partnership means a shared commitment to advancing clinical research in South Korea and contributing to the global development of regenerative medicine and advanced clinical trials.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech and small to mid-size companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Fierce CRO 2024 Excellence Award in Clinical Trial Management and Global Operations, Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena 2024 Excellence Awards in Business Expansion, Innovation and Marketing, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317570511/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Investment Is Outpacing Organizations' Ability to Realize Value, New HTEC Research Finds15.9.2026 14:47:00 CEST | Press release
Global survey of 1,500 C-level executives shows value realization sits at the intersection of investment, organizational readiness, governance and ability to measure desired outcomes and warns of a widening gap that is bottlenecking returns on AI. HTEC, a global product engineering and AI transformation company, today released preview findings from its AI Value Realization Report 2026, based on a survey of 1,500 C-level executives across the US, UK, Germany, and the UAE. The research reveals that AI investment is accelerating faster than organizations' ability to absorb it — creating a growing bottleneck between what companies are spending on AI and the value they are actually able to realize from it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915718678/en/ HTEC, a global product engineering and AI transformation company, today released preview findings from its AI Value Realization Report 2026, based on a survey of 1
Telness Tech Becomes Valdyr, Making Seamless OS the AI-Native Execution Layer for Telecom Operators15.9.2026 14:30:00 CEST | Press release
The company behind Seamless OS, now serving Telia and Truecaller, takes a new name as it turns to making large established operators AI-native. Valdyr positions Seamless OS as the AI-native execution layer for telecom operators: the layer on which commercial decisions are carried out, rather than a system of record that reports on them. Offers, subscriptions, billing, provisioning, customer journeys and integrations run in one place, telecom processes are built as automated workflows instead of custom development, and AI is applied to commercial and customer-facing operations inside the platform rather than sold as a separate product. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915818094/en/ Telness Tech is rebranding and becoming Valdyr The platform supports operators across the United States, Europe and beyond. Recent additions include Telia, the Nordic incumbent operator, and Truecaller, the caller-identification co
BMC TV expands UK network for major sports broadcasts with Adtran and Fibre Technologies Ltd15.9.2026 14:00:00 CEST | Press release
News summary: Rising capacity and performance demands for live sports are driving new requirements at the broadcast network edge Adtran’s packet edge solution enables BMC TV to reliably aggregate and distribute live feeds across its LMX Live nationwide network Scalable, deterministic architecture supports major live sports events today while providing a path to 400G services Adtran today announced that BMC TV has expanded its UK core network, harnessing Adtran technology to support coverage of major events, including the FIFA World Cup and extensive racecourse broadcasting across the UK. The new infrastructure strengthens BMC TV’s packet edge, access and aggregation layers, enabling reliable distribution of live feeds across multiple locations with deterministic, low-latency performance. Designed to scale with growing broadcast demands, the network also provides a clear route to future 400Gbit/s services. The deployment was delivered in partnership with Fibre Technologies Ltd, which le
Two Powerhouses, One Drive: SharkNinja Joins McLaren Racing as Official Partner15.9.2026 14:00:00 CEST | Press release
Global partnership includes exclusive content, fan experiences, and driver and ambassador collaborationsSharkNinja will work with the McLaren Racing Accelerator Program, drawing on McLaren’s engineering expertise to help shape future SharkNinja products SharkNinja, Inc. (NYSE: SN), a global product design and technology company, is proud to announce its new global partnership with McLaren Racing, the renowned British motorsport team, across its Formula 1, IndyCar, World Endurance Championship, and F1 Academy entries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915026788/en/ As an Official Partner, SharkNinja will become part of the McLaren Racing ecosystem through exclusive experiences, content, and activations designed to connect fans with the ethos and innovation of the two brands. Through the McLaren Racing Accelerator Program, engineers from both companies will work together to apply advanced racing methodologies t
The LYCRA Company Appoints Hua Du as Chief Executive Officer15.9.2026 14:00:00 CEST | Press release
The LYCRA Company, a global leader in developing fiber and technology solutions for the apparel and personal care industries, announced today that Hua Du has been appointed chief executive officer, effective September 14, as the company enters its next chapter following the successful completion of its financial restructuring. Du succeeds Dean Williams, who served as interim chief executive officer and will continue in his role as chief financial officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915565505/en/ The LYCRA Company Appoints Hua Du as Chief Executive Officer. With 30 years of leadership experience in the specialty chemical and biotechnology industries, Du is well positioned to lead the company into its next chapter. Du brings 30 years of leadership experience in the specialty chemical and biotech-based industries, driving transformational growth across global businesses. Du most recently served as CEO of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom